Publications by authors named "Michael Misel"

Limited case series describe conflicting results regarding the safety of checkpoint inhibitors (CPI) prior to liver transplantation (LT). We reviewed single-center data on all consecutive patients who underwent LT for hepatocellular carcinoma treated with CPI between January 1, 2018, and January 30, 2021. Time from CPI to LT, immunosuppression, biopsy-proven acute cellular rejection (BPACR), graft loss and death were evaluated.

View Article and Find Full Text PDF

Sex plays a role in the incidence and progression of a wide variety of diseases and conditions related to transplantation. Additionally, a growing body of clinical and experimental evidence suggests that sex can impact the pharmacokinetics and pharmacodynamics of several commonly used immunosuppressive and anti-infective drugs in transplant recipients. A better understanding of these sex differences will facilitate advances in individualizing treatment for patients and improve outcomes of solid organ transplantation.

View Article and Find Full Text PDF

On June 18, 2013, the United Network for Organ Sharing (UNOS) instituted a change in the liver transplant allocation policy known as "Share 35." The goal was to decrease waitlist mortality by increasing regional sharing of livers for patients with a model for end-stage liver disease (MELD) score of 35 or above. Several studies have shown Share 35 successful in reducing waitlist mortality, particularly in patients with high MELD.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatic encephalopathy (HE) is a serious, often reversible brain-related complication that can occur in patients with liver cirrhosis and other metabolic disorders, characterized by cognitive and mood changes, muscle issues, and sleep disturbances.
  • Standard treatments like lactulose and rifaximin are commonly used, but they can have side effects and may not work for everyone, creating a need for additional therapies.
  • Sodium benzoate is an alternative adjunctive treatment that could help some patients who don't respond to standard therapies, but its benefits are not fully proven, and it may not be suitable for those with specific health issues like kidney dysfunction.
View Article and Find Full Text PDF

With the goal of providing guidance on the provision of optimal intensive care to adult patients with acute liver failure (ALF), this paper defines ALF and describes a protocol for appropriately diagnosing this relatively rare clinical entity and ascertaining its etiology, where possible. This paper also identifies the few known therapies that may be effective for specific causes of ALF and provides a comprehensive approach for anticipating, identifying, and managing complications. Finally, one of the more important aspects of care for patients with ALF is the determination of prognosis and, specifically, the need for liver transplantation.

View Article and Find Full Text PDF